Browsing Tag
GSK
43 posts
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
Clover Biopharmaceuticals stock in focus as new RSV re-vaccination data targets a gap GSK has not solved
Clover Biopharmaceuticals says new RSV re-vaccination data beat Arexvy in older adults. Read what this could mean for the adult vaccine market.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
GSK bets on activin signalling with $950m 35Pharma acquisition
Discover why GSK plc is acquiring 35Pharma Inc. for $950 million and what HS235 could mean for the future of pulmonary hypertension treatment.